FDA Accepts MyMD Pharmaceuticals Investigational New Drug Application for Phase 2 Study of oral TNF- inhibitor MYMD-1 in Rheumatoid Arthritis
MYMDDelisted Stock | USD 1.82 0.02 1.09% |
About 61% of MyMD Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in MyMD Pharmaceuticals suggests that many traders are alarmed regarding MyMD Pharmaceuticals' prospects. The current market sentiment, together with MyMD Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use MyMD Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
MyMD |
BALTIMORE, August 14, 2023 MyMD Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced today that the U.S. Food and Drug Administration has accepted the Companys Investigational New Drug Application to evaluate the safety, efficacy, pharmacodynamics and pharmacokinetics of oral TNF- inhibitor MYMD-1 in patients wi
Read at finance.yahoo.com
MyMD Pharmaceuticals Fundamental Analysis
We analyze MyMD Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MyMD Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MyMD Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Debt To Equity
Debt To Equity Comparative Analysis
MyMD Pharmaceuticals is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
MyMD Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MyMD Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of MyMD Pharmaceuticals could also be used in its relative valuation, which is a method of valuing MyMD Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
MyMD Pharmaceuticals Related Equities
SRZN | Surrozen | 20.75 | ||||
REVB | Revelation Biosciences | 16.67 | ||||
NVCT | Nuvectis Pharma | 9.25 | ||||
LYEL | Lyell Immunopharma | 6.51 | ||||
LYRA | Lyra Therapeutics | 5.88 | ||||
LRMR | Larimar Therapeutics | 5.82 | ||||
RXRX | Recursion Pharmaceuticals | 5.80 | ||||
NBY | NovaBay Pharmaceuticals | 5.56 | ||||
KZR | Kezar Life | 4.27 | ||||
GOVX | GeoVax Labs | 3.98 | ||||
UBX | Unity Biotechnology | 3.00 | ||||
REPL | Replimune | 2.32 | ||||
DSGN | Design Therapeutics | 2.20 | ||||
ORIC | Oric Pharmaceuticals | 1.83 | ||||
PASG | Passage Bio | 1.52 | ||||
GOSS | Gossamer Bio | 1.19 | ||||
LGND | Ligand Pharmaceuticals | 0.77 | ||||
KROS | Keros Therapeutics | 0.60 | ||||
BOLT | Bolt Biotherapeutics | 0.06 | ||||
AVIR | Atea Pharmaceuticals | 0.00 | ||||
XBIO | Xenetic Biosciences | 2.65 | ||||
KRON | Kronos Bio | 3.16 |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in MyMD Stock
If you are still planning to invest in MyMD Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MyMD Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |